Drug intelligence / Profile preview

DPX-rHA

Development stage: Preclinical
Lead developer: BioVaxys Technology Corporation
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

DPX-rHA is an investigational recombinant protein subunit vaccine for the prevention of influenza, developed by BioVaxys Technology Corp. It utilizes the proprietary DPX (DepoVax) delivery platform, a lipid-in-oil formulation designed to facilitate the delivery of antigens to regional lymph nodes and stimulate robust, long-lasting T cell and B cell immune responses. The active component is a recombinant hemagglutinin (rHA) protein. In preclinical studies, DPX-rHA has demonstrated superior antibody durability and protection against multiple influenza strains, including H1N1 and H3N2, compared to standard alum-adjuvanted formulations.

Other names: DPX-rHA influenza vaccine

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on DPX-rHA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DPX-rHA.

Explore the full profile